Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 108

1.

Chocolate Consumers and Lymphocyte-to-Monocyte Ratio: A Working Hypothesis from a Preliminary Report of a Pilot Study in Celiac Subjects.

Raguzzini A, Poce G, Consalvi S, Toti E, Palmacci F, Biava M, Peluso I.

Antioxidants (Basel). 2019 Oct 1;8(10). pii: E440. doi: 10.3390/antiox8100440.

2.

Dietary flavonoids: Nano delivery and nanoparticles for cancer therapy.

Aiello P, Consalvi S, Poce G, Raguzzini A, Toti E, Palmery M, Biava M, Bernardi M, Kamal MA, Perry G, Peluso I.

Semin Cancer Biol. 2019 Aug 24. pii: S1044-579X(19)30217-2. doi: 10.1016/j.semcancer.2019.08.029. [Epub ahead of print] Review.

PMID:
31454670
3.

Pulmonary Involvement during the Ebola Virus Disease.

Lalle E, Biava M, Nicastri E, Colavita F, Di Caro A, Vairo F, Lanini S, Castilletti C, Langer M, Zumla A, Kobinger G, Capobianchi MR, Ippolito G.

Viruses. 2019 Aug 24;11(9). pii: E780. doi: 10.3390/v11090780. Review.

4.

Neutrophil-to-Lymphocyte Ratio, Mediterranean Diet, and Bone Health in Coeliac Disease Patients: A Pilot Study.

Palmacci F, Toti E, Raguzzini A, Catasta G, Aiello P, Peluso I, Biava M, Palmery M.

Oxid Med Cell Longev. 2019 Jun 20;2019:7384193. doi: 10.1155/2019/7384193. eCollection 2019.

5.

Efficacy and steroid-sparing effect of benralizumab: has it an advantage over its competitors?

Menzella F, Biava M, Bagnasco D, Galeone C, Simonazzi A, Ruggiero P, Facciolongo N.

Drugs Context. 2019 Apr 15;8:212580. doi: 10.7573/dic.212580. eCollection 2019. Review.

6.

Inflammatory and Humoral Immune Response during Ebola Virus Infection in Survivor and Fatal Cases Occurred in Sierra Leone during the 2014⁻2016 Outbreak in West Africa.

Colavita F, Biava M, Castilletti C, Lanini S, Miccio R, Portella G, Vairo F, Ippolito G, Capobianchi MR, Di Caro A, Lalle E.

Viruses. 2019 Apr 23;11(4). pii: E373. doi: 10.3390/v11040373.

7.

Severe refractory asthma: current treatment options and ongoing research.

Menzella F, Bertolini F, Biava M, Galeone C, Scelfo C, Caminati M.

Drugs Context. 2018 Dec 5;7:212561. doi: 10.7573/dic.212561. eCollection 2018. Review.

8.

In vitro comprehensive analysis of VA692 a new chemical entity for the treatment of osteoarthritis.

Cheleschi S, Calamia V, Fernandez-Moreno M, Biava M, Giordani A, Fioravanti A, Anzini M, Blanco F.

Int Immunopharmacol. 2018 Nov;64:86-100. doi: 10.1016/j.intimp.2018.08.025. Epub 2018 Aug 25.

PMID:
30153531
9.

Introduction to COX inhibitors.

Biava M.

Future Med Chem. 2018 Aug 1;10(15):1737-1740. doi: 10.4155/fmc-2018-0159. Epub 2018 Jul 18. No abstract available.

10.

ZIKV Infection Induces an Inflammatory Response but Fails to Activate Types I, II, and III IFN Response in Human PBMC.

Colavita F, Bordoni V, Caglioti C, Biava M, Castilletti C, Bordi L, Quartu S, Iannetta M, Ippolito G, Agrati C, Capobianchi MR, Lalle E.

Mediators Inflamm. 2018 Jun 3;2018:2450540. doi: 10.1155/2018/2450540. eCollection 2018.

11.

In vivo potent BM635 analogue with improved drug-like properties.

Poce G, Cocozza M, Alfonso S, Consalvi S, Venditti G, Fernandez-Menendez R, Bates RH, Barros Aguirre D, Ballell L, De Logu A, Vistoli G, Biava M.

Eur J Med Chem. 2018 Feb 10;145:539-550. doi: 10.1016/j.ejmech.2017.12.075. Epub 2017 Dec 27.

PMID:
29335214
12.

Evaluation of a rapid and sensitive RT-qPCR assay for the detection of Ebola Virus.

Biava M, Colavita F, Marzorati A, Russo D, Pirola D, Cocci A, Petrocelli A, Delli Guanti M, Cataldi G, Kamara TA, Kamara AS, Konneh K, Cannas A, Coen S, Quartu S, Meschi S, Valli MB, Mazzarelli A, Venditti C, Grassi G, Rozera G, Castilletti C, Mirazimi A, Capobianchi MR, Ippolito G, Miccio R, Di Caro A.

J Virol Methods. 2018 Feb;252:70-74. doi: 10.1016/j.jviromet.2017.11.009. Epub 2017 Nov 21.

PMID:
29170019
13.

Persistence of ZIKV-RNA in the cellular fraction of semen is accompanied by a surrogate-marker of viral replication. Diagnostic implications for sexual transmission.

Biava M, Caglioti C, Castilletti C, Bordi L, Carletti F, Colavita F, Quartu S, Nicastri E, Iannetta M, Vairo F, Liuzzi G, Taglietti F, Ippolito G, Capobianchi MR, Lalle E.

New Microbiol. 2018 Jan;41(1):30-33. Epub 2017 Nov 7.

14.

EBOLA Ag K-SeT rapid test: field evaluation in Sierra Leone.

Colavita F, Biava M, Mertens P, Gilleman Q, Borlon C, Delli Guanti M, Petrocelli A, Cataldi G, Kamara AT, Kamara SA, Konneh K, Vincenti D, Castilletti C, Abdurahman S, Mirazimi A, Capobianchi MR, Ippolito G, Miccio R, Di Caro A.

Clin Microbiol Infect. 2018 Jun;24(6):653-657. doi: 10.1016/j.cmi.2017.10.019. Epub 2017 Oct 26.

15.

Deep Sequencing of RNA from Blood and Oral Swab Samples Reveals the Presence of Nucleic Acid from a Number of Pathogens in Patients with Acute Ebola Virus Disease and Is Consistent with Bacterial Translocation across the Gut.

Carroll MW, Haldenby S, Rickett NY, Pályi B, Garcia-Dorival I, Liu X, Barker G, Bore JA, Koundouno FR, Williamson ED, Laws TR, Kerber R, Sissoko D, Magyar N, Di Caro A, Biava M, Fletcher TE, Sprecher A, Ng LFP, Rénia L, Magassouba N, Günther S, Wölfel R, Stoecker K, Matthews DA, Hiscox JA.

mSphere. 2017 Aug 23;2(4). pii: e00325-17. doi: 10.1128/mSphereDirect.00325-17. eCollection 2017 Jul-Aug.

16.

Measles Cases during Ebola Outbreak, West Africa, 2013-2106.

Colavita F, Biava M, Castilletti C, Quartu S, Vairo F, Caglioti C, Agrati C, Lalle E, Bordi L, Lanini S, Guanti MD, Miccio R, Ippolito G, Capobianchi MR, Di Caro A; Lazzaro Spallanzani Institute for Research and Health Care Ebola Virus Disease Sierra Leone Study Group.

Emerg Infect Dis. 2017 Jun;23(6):1035-1037. doi: 10.3201/eid2306.161682.

17.

Detection of Viral RNA in Tissues following Plasma Clearance from an Ebola Virus Infected Patient.

Biava M, Caglioti C, Bordi L, Castilletti C, Colavita F, Quartu S, Nicastri E, Lauria FN, Petrosillo N, Lanini S, Hoenen T, Kobinger G, Zumla A, Di Caro A, Ippolito G, Capobianchi MR, Lalle E.

PLoS Pathog. 2017 Jan 5;13(1):e1006065. doi: 10.1371/journal.ppat.1006065. eCollection 2017 Jan.

18.

Pharmaceutical salt of BM635 with improved bioavailability.

Poce G, Consalvi S, Cocozza M, Fernandez-Menendez R, Bates RH, Ortega Muro F, Barros Aguirre D, Ballell L, Biava M.

Eur J Pharm Sci. 2017 Mar 1;99:17-23. doi: 10.1016/j.ejps.2016.12.003. Epub 2016 Dec 8.

PMID:
27939618
19.

Enabling Rapid Response to the 2014-2016 Ebola Epidemic: The Experience and the Results of the National Institute for Infectious Diseases Lazzaro Spallanzani.

Nicastri E, Castilletti C, Biava M, Fusco FM, Petrosillo N, Puro V, Lauria FN, Capobianchi MR, Di Caro A, Ippolito G.

Adv Exp Med Biol. 2017;972:103-122. doi: 10.1007/5584_2016_134.

PMID:
27864803
20.

A Series of COX-2 Inhibitors Endowed with NO-Releasing Properties: Synthesis, Biological Evaluation, and Docking Analysis.

Consalvi S, Poce G, Ragno R, Sabatino M, La Motta C, Sartini S, Calderone V, Martelli A, Ghelardini C, Di Cesare Mannelli L, Biava M.

ChemMedChem. 2016 Aug 19;11(16):1804-11. doi: 10.1002/cmdc.201600086. Epub 2016 May 27.

PMID:
27229194
21.

(E)-3-Heteroarylidenechroman-4-ones as potent and selective monoamine oxidase-B inhibitors.

Desideri N, Proietti Monaco L, Fioravanti R, Biava M, Yáñez M, Alcaro S, Ortuso F.

Eur J Med Chem. 2016 Jul 19;117:292-300. doi: 10.1016/j.ejmech.2016.03.081. Epub 2016 Mar 29.

PMID:
27135371
22.

MmpL3 Inhibitors: Diverse Chemical Scaffolds Inhibit the Same Target.

Poce G, Consalvi S, Biava M.

Mini Rev Med Chem. 2016;16(16):1274-1283. Review.

PMID:
26776226
23.

Synthesis and biological evaluation of fluorinated 1,5-diarylpyrrole-3-alkoxyethyl ether derivatives as selective COX-2 inhibitors endowed with anti-inflammatory activity.

Di Capua A, Sticozzi C, Brogi S, Brindisi M, Cappelli A, Sautebin L, Rossi A, Pace S, Ghelardini C, Di Cesare Mannelli L, Valacchi G, Giorgi G, Giordani A, Poce G, Biava M, Anzini M.

Eur J Med Chem. 2016 Feb 15;109:99-106. doi: 10.1016/j.ejmech.2015.12.044. Epub 2015 Dec 28.

PMID:
26774035
24.

COX inhibitors: a patent review (2011 - 2014).

Consalvi S, Biava M, Poce G.

Expert Opin Ther Pat. 2015;25(12):1357-71. doi: 10.1517/13543776.2015.1090973. Epub 2015 Nov 13. Review.

PMID:
26566186
25.

Overcoming drug resistance for tuberculosis.

Poce G, Biava M.

Future Microbiol. 2015;10(11):1735-41. doi: 10.2217/fmb.15.76. Epub 2015 Oct 30. Review.

PMID:
26516679
26.

Molecular Signature of the Ebola Virus Associated with the Fishermen Community Outbreak in Aberdeen, Sierra Leone, in February 2015.

Capobianchi MR, Gruber CE, Carletti F, Meschi S, Castilletti C, Vairo F, Biava M, Minosse C, Strada G, Portella G, Miccio R, Minardi V, Rolla L, Kamara A, Chillemi G, Desideri A, Di Caro A, Ippolito G.

Genome Announc. 2015 Sep 24;3(5). pii: e01093-15. doi: 10.1128/genomeA.01093-15.

27.

Chondroprotective effect of three different classes of anti-inflammatory agents on human osteoarthritic chondrocytes exposed to IL-1β.

Cheleschi S, Pascarelli NA, Valacchi G, Di Capua A, Biava M, Belmonte G, Giordani A, Sticozzi C, Anzini M, Fioravanti A.

Int Immunopharmacol. 2015 Sep;28(1):794-801. doi: 10.1016/j.intimp.2015.07.003. Epub 2015 Aug 26.

PMID:
26292179
28.

Activity of lipophilic and hydrophilic drugs against dormant and replicating Mycobacterium tuberculosis.

Piccaro G, Poce G, Biava M, Giannoni F, Fattorini L.

J Antibiot (Tokyo). 2015 Nov;68(11):711-4. doi: 10.1038/ja.2015.52. Epub 2015 May 6. No abstract available.

PMID:
25944535
29.

N-((1,3-Diphenyl-1H-pyrazol-4-yl)methyl)anilines: A novel class of anti-RSV agents.

Fioravanti R, Desideri N, Biava M, Droghini P, Atzori EM, Ibba C, Collu G, Sanna G, Delogu I, Loddo R.

Bioorg Med Chem Lett. 2015 Jun 1;25(11):2401-4. doi: 10.1016/j.bmcl.2015.04.006. Epub 2015 Apr 9.

PMID:
25913116
30.

A novel antimycobacterial compound acts as an intracellular iron chelator.

Dragset MS, Poce G, Alfonso S, Padilla-Benavides T, Ioerger TR, Kaneko T, Sacchettini JC, Biava M, Parish T, Argüello JM, Steigedal M, Rubin EJ.

Antimicrob Agents Chemother. 2015 Apr;59(4):2256-64. doi: 10.1128/AAC.05114-14. Epub 2015 Feb 2.

31.

Synthesis, biological evaluation and docking analysis of a new series of methylsulfonyl and sulfamoyl acetamides and ethyl acetates as potent COX-2 inhibitors.

Consalvi S, Alfonso S, Di Capua A, Poce G, Pirolli A, Sabatino M, Ragno R, Anzini M, Sartini S, La Motta C, Di Cesare Mannelli L, Ghelardini C, Biava M.

Bioorg Med Chem. 2015 Feb 15;23(4):810-20. doi: 10.1016/j.bmc.2014.12.041. Epub 2014 Dec 26.

PMID:
25596758
32.

Murine granulocyte-macrophage colony-stimulating factor expressed from a bicistronic simian immunodeficiency virus-based integrase-defective lentiviral vector does not enhance T-cell responses in mice.

Michelini Z, Negri D, Biava M, Baroncelli S, Spada M, Leone P, Bona R, Blasi M, Nègre D, Klotman ME, Cara A.

Viral Immunol. 2014 Dec;27(10):512-20. doi: 10.1089/vim.2014.0062.

PMID:
25343523
33.

SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development.

Poce G, Cocozza M, Consalvi S, Biava M.

Eur J Med Chem. 2014 Oct 30;86:335-51. doi: 10.1016/j.ejmech.2014.08.066. Epub 2014 Aug 27. Review.

PMID:
25173852
34.

Flow Synthesis and Biological Studies of an Analgesic Adamantane Derivative That Inhibits P2X7-Evoked Glutamate Release.

Battilocchio C, Guetzoyan L, Cervetto C, Di Cesare Mannelli L, Frattaroli D, Baxendale IR, Maura G, Rossi A, Sautebin L, Biava M, Ghelardini C, Marcoli M, Ley SV.

ACS Med Chem Lett. 2013 May 22;4(8):704-9. doi: 10.1021/ml400079h. eCollection 2013 Aug 8.

35.

Enhancing the pharmacodynamic profile of a class of selective COX-2 inhibiting nitric oxide donors.

Biava M, Battilocchio C, Poce G, Alfonso S, Consalvi S, Di Capua A, Calderone V, Martelli A, Testai L, Sautebin L, Rossi A, Ghelardini C, Di Cesare Mannelli L, Giordani A, Persiani S, Colovic M, Dovizio M, Patrignani P, Anzini M.

Bioorg Med Chem. 2014 Jan 15;22(2):772-86. doi: 10.1016/j.bmc.2013.12.008. Epub 2013 Dec 18.

PMID:
24373735
36.

The novel anti-inflammatory agent VA694, endowed with both NO-releasing and COX2-selective inhibiting properties, exhibits NO-mediated positive effects on blood pressure, coronary flow and endothelium in an experimental model of hypertension and endothelial dysfunction.

Martelli A, Testai L, Anzini M, Cappelli A, Di Capua A, Biava M, Poce G, Consalvi S, Giordani A, Caselli G, Rovati L, Ghelardini C, Patrignani P, Sautebin L, Breschi MC, Calderone V.

Pharmacol Res. 2013 Dec;78:1-9. doi: 10.1016/j.phrs.2013.09.008. Epub 2013 Sep 29.

PMID:
24083950
37.

Design, synthesis, and in vitro hMAO-B inhibitory evaluation of some 1-methyl-3,5-diphenyl-4,5-dihydro-1H-pyrazoles.

Fioravanti R, Desideri N, Biava M, Proietti Monaco L, Grammatica L, Yáñez M.

Bioorg Med Chem Lett. 2013 Sep 15;23(18):5128-30. doi: 10.1016/j.bmcl.2013.07.035. Epub 2013 Jul 23.

PMID:
23927971
38.

Identification of Hck inhibitors as hits for the development of antileukemia and anti-HIV agents.

Tintori C, Laurenzana I, La Rocca F, Falchi F, Carraro F, Ruiz A, Esté JA, Kissova M, Crespan E, Maga G, Biava M, Brullo C, Schenone S, Botta M.

ChemMedChem. 2013 Aug;8(8):1353-60. doi: 10.1002/cmdc.201300204. Epub 2013 Jun 28.

PMID:
23813855
39.

Inhibition of Leishmania infantum trypanothione reductase by azole-based compounds: a comparative analysis with its physiological substrate by X-ray crystallography.

Baiocco P, Poce G, Alfonso S, Cocozza M, Porretta GC, Colotti G, Biava M, Moraca F, Botta M, Yardley V, Fiorillo A, Lantella A, Malatesta F, Ilari A.

ChemMedChem. 2013 Jul;8(7):1175-83. doi: 10.1002/cmdc.201300176. Epub 2013 Jun 3.

PMID:
23733388
40.

A class of pyrrole derivatives endowed with analgesic/anti-inflammatory activity.

Battilocchio C, Poce G, Alfonso S, Porretta GC, Consalvi S, Sautebin L, Pace S, Rossi A, Ghelardini C, Di Cesare Mannelli L, Schenone S, Giordani A, Di Francesco L, Patrignani P, Biava M.

Bioorg Med Chem. 2013 Jul 1;21(13):3695-701. doi: 10.1016/j.bmc.2013.04.031. Epub 2013 Apr 26.

PMID:
23680444
41.

Pharmacophore assessment through 3-D QSAR: evaluation of the predictive ability on new derivatives by the application on a series of antitubercular agents.

Friggeri L, Ballante F, Ragno R, Musmuca I, De Vita D, Manetti F, Biava M, Scipione L, Di Santo R, Costi R, Feroci M, Tortorella S.

J Chem Inf Model. 2013 Jun 24;53(6):1463-74. doi: 10.1021/ci400132q. Epub 2013 May 17.

PMID:
23617317
42.

Characterization of the biotransformation pathways of clomiphene, tamoxifen and toremifene as assessed by LC-MS/(MS) following in vitro and excretion studies.

Mazzarino M, Biava M, de la Torre X, Fiacco I, Botrè F.

Anal Bioanal Chem. 2013 Jun;405(16):5467-87. doi: 10.1007/s00216-013-6961-7. Epub 2013 Apr 23.

PMID:
23604525
43.

Novel analgesic/anti-inflammatory agents: 1,5-diarylpyrrole nitrooxyalkyl ethers and related compounds as cyclooxygenase-2 inhibiting nitric oxide donors.

Anzini M, Di Capua A, Valenti S, Brogi S, Rovini M, Giuliani G, Cappelli A, Vomero S, Chiasserini L, Sega A, Poce G, Giorgi G, Calderone V, Martelli A, Testai L, Sautebin L, Rossi A, Pace S, Ghelardini C, Di Cesare Mannelli L, Benetti V, Giordani A, Anzellotti P, Dovizio M, Patrignani P, Biava M.

J Med Chem. 2013 Apr 25;56(8):3191-206. doi: 10.1021/jm301370e. Epub 2013 Apr 11. Erratum in: J Med Chem. 2013 Jun 13;56(11):4821.

PMID:
23534442
44.

Antiproliferative effect of two novel COX-2 inhibitors on human keratinocytes.

Sticozzi C, Belmonte G, Cervellati F, Di Capua A, Maioli E, Cappelli A, Giordani A, Biava M, Anzini M, Valacchi G.

Eur J Pharm Sci. 2013 May 13;49(2):133-41. doi: 10.1016/j.ejps.2013.02.009. Epub 2013 Feb 26.

PMID:
23454135
45.

Improved BM212 MmpL3 inhibitor analogue shows efficacy in acute murine model of tuberculosis infection.

Poce G, Bates RH, Alfonso S, Cocozza M, Porretta GC, Ballell L, Rullas J, Ortega F, De Logu A, Agus E, La Rosa V, Pasca MR, De Rossi E, Wae B, Franzblau SG, Manetti F, Botta M, Biava M.

PLoS One. 2013;8(2):e56980. doi: 10.1371/journal.pone.0056980. Epub 2013 Feb 21.

46.

1,5-Diphenylpenta-2,4-dien-1-ones as potent and selective monoamine oxidase-B inhibitors.

Desideri N, Fioravanti R, Proietti Monaco L, Biava M, Yáñez M, Ortuso F, Alcaro S.

Eur J Med Chem. 2013 Jan;59:91-100. doi: 10.1016/j.ejmech.2012.11.006. Epub 2012 Nov 15.

PMID:
23207410
47.

Improving the solubility of a new class of antiinflammatory pharmacodynamic hybrids, that release nitric oxide and inhibit cycloxygenase-2 isoenzyme.

Biava M, Battilocchio C, Poce G, Alfonso S, Consalvi S, Porretta GC, Schenone S, Calderone V, Martelli A, Testai L, Ghelardini C, Di Cesare Mannelli L, Sautebin L, Rossi A, Giordani A, Patrignani P, Anzini M.

Eur J Med Chem. 2012 Dec;58:287-98. doi: 10.1016/j.ejmech.2012.10.014. Epub 2012 Oct 18.

PMID:
23131542
48.

In vitro effects of VA441, a new selective cyclooxygenase-2 inhibitor, on human osteoarthritic chondrocytes exposed to IL-1β.

Fioravanti A, Tinti L, Pascarelli NA, Di Capua A, Lamboglia A, Cappelli A, Biava M, Giordani A, Niccolini S, Galeazzi M, Anzini M.

J Pharmacol Sci. 2012;120(1):6-14. Epub 2012 Aug 8.

49.

MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212.

La Rosa V, Poce G, Canseco JO, Buroni S, Pasca MR, Biava M, Raju RM, Porretta GC, Alfonso S, Battilocchio C, Javid B, Sorrentino F, Ioerger TR, Sacchettini JC, Manetti F, Botta M, De Logu A, Rubin EJ, De Rossi E.

Antimicrob Agents Chemother. 2012 Jan;56(1):324-31. doi: 10.1128/AAC.05270-11. Epub 2011 Oct 24.

50.

Novel analgesic/anti-inflammatory agents: diarylpyrrole acetic esters endowed with nitric oxide releasing properties.

Biava M, Porretta GC, Poce G, Battilocchio C, Alfonso S, Rovini M, Valenti S, Giorgi G, Calderone V, Martelli A, Testai L, Sautebin L, Rossi A, Papa G, Ghelardini C, Di Cesare Mannelli L, Giordani A, Anzellotti P, Bruno A, Patrignani P, Anzini M.

J Med Chem. 2011 Nov 24;54(22):7759-71. doi: 10.1021/jm200715n. Epub 2011 Oct 31.

PMID:
21992176

Supplemental Content

Support Center